Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on I-thyroxine-suppressive therapy for differentiated thyroid carcinoma

Hormone Research

Volumn 64, Issue 2, 2005, Pages 100-106

  Murialdo, G ^a   Casu, M ^a   Cappi, C ^a   Patrone, V ^a   Repetto, E ^a   Copello, F ^b   Minuto, F ^a   Giusti, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Autonomic system; Differentiated thyroid cancer; Heart rate variability; Power spectral analysis; Recombinant human; TSH

Indexed keywords

RECOMBINANT THYROTROPIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEADACHE; HEART RATE VARIABILITY; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE; THYROID CARCINOMA;

ADULT; AGED; ANTITHYROID AGENTS; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 26444551264     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088429     Document Type: Article

References (26)

1. Basaria M, Graf H, Cooper DS: The use of recombinant thyrotropin in the follow-up of patients with differentiated thyroid cancer. Am J Med 2002;112:721-725.
2. Wartofsky L: Management of low-risk well-differentiated thyroid cancer based on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002;12:583-590.
3. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A: Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-3673.
4. Fazio S, Biondi B, Lupoli G, Cittadini A, Santomauro M, Tommaselli AP, Lombardi G, Sacca L: Evaluation by noninvasive method of the effects of acute loss of thyroid hormone on the heart. Angiology 1992;43:287-293.
5. Botella-Carretero JI, Gomez-Bueno M, Barrios V, Caballero C, Garcia-Robles R, Sancho J, Escobar-Morreale HF: Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2004;11:345-356.
6. Guidelines. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354-381.
7. Sellitti DF, Hill R, Doi SQ, Akamizu T, Czaja J, Tao S, Koshiyama H: Differential expression of thyrotropin receptor mRNA in the porcine heart. Thyroid 1996;7:641-646.
8. Busuttil BE, Frauman AG: Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac muscle tissues. J Clin Endocrinol Metab 2001;86:2315-2319.
9. Busuttil BE, Frauman AG: TSH receptor expression in cardiac muscle tissue. J Clin Endocrinol Metab 2002;87:2994.
10. Sellitti DF, Dennison D, Akamazu T, Doi SQ, Kohn LD, Kashiyama B: Thyrotropin regulation of cyclic adenosine monophosphate production in human coronary artery smooth muscle cells. Thyroid 2000;10:219-225.
11. Casu M, Cappi C, Patrone V, Repetto E, Giusti M, Minuto F, Murialdo G: Sympatho-vagal control of heart rate variability in patients treated with suppressive doses of 1-thyroxine for thyroid cancer. Eur J Endocrinol 2005;152:819-824.
12. Malliani A, Pagani M, Lombardi F, Cerutti S: Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;84:482-491.
13. Pagani M, Lombardi F, Guzzetti S, Rimordi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga F: Power spectral analysis of heart rate and arterial pressure variability as a marker of sympatho-vagal interaction in man and in conscious dog. Circ Res 1986;59:178-193.
14. Bernardi L, Leuzzi S, Radaelli A, Passino C, Johnston JA, Sleight P: Low-frequency spontaneous fluctuations of R-R interval and blood pressure in conscious humans: a baroreceptor or central phenomenon? Clin Sci 1994;87:649-654.
15. Lipsitz LA, Mietus J, Moody GB, Goldberger AL: Spectral characteristics of heart rate variability before and during postural tilt. Circulation 1990;81:1803-1810.
16. Petretta M, Bonaduce D, Spinelli L, Vicario MLE, Nuzzo V, Marciano F, Camuso P, De Sanctis V, Lupoli G: Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 2001;145:691-696.
17. Goichot B, Brandenberger G, Vinzio S, Perrin AE, Geny B, Schlienger JL, Simon C: Sympathovagal response to orthostatism in overt and in subclinical hyperthyroidism. J Endocrinol Invest 2004;27:348-352.
18. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L: Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224-4228.
19. Fazio S, Palmieri EA, Lombardi G, Biondi B: Effects of thyroid hormones on the cardiovascular system. Recent Prog Horm Res 2004;59:31-50.
20. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S: Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effects of individual dose tailoring. J Clin Endocrinol Metab 2000;85:159-164.
21. Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G, Fazio S: Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. J Clin Endocrinol Metab 2003;88:211-214.
22. Drvota V, Janson A, Norman C, Sylven C, Haggblad J, Bronnegard M, Marcus C: Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem Biophys Res Commun 1995;211:426-431.
23. Giusti M, Valenti S, Guazzini E, Molinari E, Cavallero D, Auferi C, Minuto F: Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant. J Endocrinol Invest 2003;26:1192-1197.
24. Kitano H, Kitanishi T, Nakanishi Y, Suzuki M, Takeuchi E, Yazawa Y, Kitajima K, Kimura H, Tooyama I: Expression of inducible nitric oxide synthase in human thyroid papillary carcinomas. Thyroid 1999;9:113-117.
25. Thomsen LL, Olesen J: Nitric oxide in primary headaches. Curr Opin Neurol 2001;14:315-321.
26. Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM, Francis GL: Nitrotyrosine, inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents. J Endocrinol Invest 2002;25:675-683.